Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis

Cancer

Volumn 115, Issue 17, 2009, Pages 3955-3968

  Palm, Thomas ^b   Figarella Branger, Dominique ^c   Chapon, Françoise ^d   Lacroix, Catherine ^e   Gray, Françoise ^f   Scaravilli, Francesco ^g   Ellison, David W ^h   Salmon, Isabelle ⁱ   Vikkula, Miikka ^b   Godfraind, Catherine ^a,j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c TIMONE HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ ERASME HOSPITAL   (Belgium)

^j UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

more..

Author keywords

Ependymoma; Expression profiling; Gene signature; Microarray; Pathways; Tumorigenesis

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR E2F; WNT PROTEIN;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; GENE EXPRESSION PROFILING; HUMANS; INFANT; MIDDLE AGED;

EID: 69249119057     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24476     Document Type: Article

References (51)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press; 2007.
2. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001;158:1137X-1143.
3. Huang B, Starostik P, Schraut H, Krauss J, Sorensen N, Roggendorf W. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol (Berl). 2003;106:357-362.
4. Mazewski C, Soukup S, Ballard E, Gotwals B, Lampkin B. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet. 1999;113:1-8.
5. Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, et al. Cytogenetic study of 33 ependymomas. Cancer Genet Cytogenet. 1999;115:96-99.
6. Zheng PP, Pang JC, Hui AB, Ng HK. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet. 2000;122:18-25.
7. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol. 2002;161:2133-2141.
8. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002;86:929-939.
9. Rousseau E, Palm T, Scaravilli F, et al. Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma [serial online]. Mol Cancer. 2007;6:47.
10. Granzow M, Popp S, Weber S, et al. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. Cancer Genet Cytogenet. 2001;130:79-83.
11. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12(7 pt 1):2070-2079.
12. Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003;29:574-583.
13. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003;163:1721-1727.
14. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24:5223-5233.
15. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8:323-335.
16. Lukashova VZI, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol (Berl). 2007;113:325-337.
17. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including 4 transcripts at 22q12.1-q13.3. Neuro Oncol. 2005;7:20-31.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
19. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol. 2008;21:165-177.
20. Zamecnik J, Snuderl M, Eckschlager T, et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol. 2003;16:980-991.
21. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007;26:6766-6776.
22. Cillo C, Cantile M, Faiella A, Boncinelli E. Homeobox genes in normal and malignant cells. J Cell Physiol. 2001;188:161-169.
23. Katoh Y, Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther. 2005;4:1050-1054.
24. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895-902.
25. Zhang XP, Zheng G, Zou L, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem. 2008;307(1-2):101-108.
26. Ward EJ, Shcherbata HR, Reynolds SH, Fischer KA, Hatfield SD, Ruohola-Baker H. Stem cells signal to the niche through the Notch pathway in the Drosophila ovary. Curr Biol. 2006;16:2352-2358.
27. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64:7794-7800.
28. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res. 2007;313:1033-1044.
29. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-765.
30. Vandeputte DA, Troost D, Leenstra S, et al. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 2002;38:329-338.
31. Cassimeris L. Cell division: eg'ing on microtubule flux. Curr Biol. 2004;14:R1000-R1002.
32. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.
33. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349-354.
34. Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol. 1998;24:434-440.
35. Ho DM, Hsu CY, Wong TT, Chiang H. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol. 2001;54:77-85.
36. Coller HA, Forman JJ, Legesse-Miller A. "Myc'ed messages": myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron [serial online]. PLoS Genet. 2007;3:e146.
37. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
38. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A. 1994;91:12823-12827.
39. Johnson DG, Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med. 2006;6:731-738.
40. Matsumura I, Tanaka H, Kanakura Y. E2F1 and c-Myc in cell growth and death. Cell Cycle. 2003;2:333-338.
41. Olson MV, Johnson DG, Jiang H, et al. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res. 2007;67:4005-4009.
42. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol. 2005;124:543-549.
43. Easwaran V, Lee SH, Inge L, et al. Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003;63:3145-3153.
44. Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol. 1998;22:816-826.
45. Preusser M, Wolfsberger S, Haberler C, et al. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol (Berl). 2005;109:211-216.
46. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155-163.
47. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993;53:3241-3245.
48. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006;166:74-81.
49. Wagner TU. Bone morphogenetic protein signaling in stem cells-1 signal, many consequences. FEBS J. 2007;274:2968-2976.
50. Akin ZN, Nazarali AJ. Hox genes and their candidate downstream targets in the developing central nervous system. Cell Mol Neurobiol. 2005;25(3-4):697-741.
51. Bapat SA. Evolution of cancer stem cells. Semin Cancer Biol. 2007;17:204-213.